CRESCENT BIOPHARMA, INC. Restructuring Costs and Asset Impairment Charges
CRESCENT BIOPHARMA, INC. (CBIO) reported Restructuring Costs and Asset Impairment Charges of $7.53 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2025-02-13
- CRESCENT BIOPHARMA, INC. restructuring costs and asset impairment charges for the quarter ending 2024-12-31 was $2.02M.
- CRESCENT BIOPHARMA, INC. restructuring costs and asset impairment charges for the quarter ending 2024-09-30 was $5.51M.
- CRESCENT BIOPHARMA, INC. restructuring costs and asset impairment charges for fiscal 2024 was $7.53M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $7.53M derived: sum of 2 quarters · filed 2025-02-13 | $7.53M 10-K · filed 2025-02-13 | |
| 2024-09-30 | $5.51M 10-Q · filed 2024-11-13 | $5.51M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |